Otilimab: Clinical Trials

11 trials of Otilimab, newest first

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

8 completed, 2 terminated, 1 withdrawn. 6 Phase 2, 4 Phase 3, 3 Phase 1.

By phase and status

Phase	Trials	Status
Phase 2	6	Completed 6
Phase 3	4	Completed 2, Terminated 2
Phase 1	3	Completed 2, Withdrawn 1

Follow Otilimab: new trials by email Literature Review of Otilimab trials Research Report on Otilimab

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
A Study in Healthy Japanese Participants to Evaluate the Safety and Pharmacokinetics of Otilimab Otilimab - Arthritis, Rheumatoid	Phase 1	Withdrawn	GlaxoSmithKline		2023-02-08	2023-01-26
Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease Otilimab, Placebo 1, Placebo 2 - Severe Acute Respiratory Syndrome	Phase 2	Completed	GlaxoSmithKline	1156	2020-05-28	2024-09-23
Long-term Safety and Efficacy of GSK3196165 (Otilimab) in the Treatment of Rheumatoid Arthritis (RA) Otilimab (GSK3196165), csDMARD(s) - Arthritis, Rheumatoid	Phase 3	Terminated	GlaxoSmithKline	2916	2020-05-12	2024-02-07
Efficacy and Safety of GSK3196165 (Otilimab) Versus Placebo and Sarilumab in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological Disease-modifying Antirheumatic Drug (DMARDs) and/or Janus Kinase (JAK) Inhibitors GSK3196165 (Otilimab), Sarilumab, Placebo to GSK3196165/ Sarilumab - Arthritis, Rheumatoid	Phase 3	Completed	GlaxoSmithKline	550	2019-10-31	2023-07-17
Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic (cs)/Biologic (b) Disease Modifying Anti-rheumatic Drugs (DMARDs) GSK3196165 (Otilimab), Tofacitinib, Placebo - Arthritis, Rheumatoid	Phase 3	Terminated	GlaxoSmithKline	1764	2019-06-05	2023-11-30
Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate GSK3196165 (Otilimab), Tofacitinib 5 mg, Placebo - Arthritis, Rheumatoid	Phase 3	Completed	GlaxoSmithKline	1537	2019-05-16	2024-03-27
Mechanistic Study of GSK3196165 Plus Methotrexate (MTX) in Subjects With Active Rheumatoid Arthritis GSK3196165, Placebo, MTX - Arthritis, Rheumatoid	Phase 2	Completed	GlaxoSmithKline	39	2016-06-15	2021-01-11
A Study to Investigate the Efficacy and Safety of GSK3196165 in Inflammatory Hand Osteoarthritis GSK3196165, Placebo - Osteoarthritis	Phase 2	Completed	GlaxoSmithKline	44	2016-03-17	2021-01-11
Study to Evaluate the Efficacy and Safety of GSK3196165 Plus Methotrexate in Subjects With Active Moderate-Severe Rheumatoid Arthritis GSK3196165, MTX, Folic acid - Arthritis, Rheumatoid	Phase 2	Completed	GlaxoSmithKline	222	2015-07-23	2021-01-11
Phase Ib Study to Evaluate MOR103 in Multiple Sclerosis MOR103, Placebo - Multiple Sclerosis	Phase 1 / Phase 2	Completed	MorphoSys AG	32	2012-01-01	2014-11-21
Safety and Preliminary Efficacy of MOR103 in Patients With Active Rheumatoid Arthritis MOR103 - Rheumatoid Arthritis	Phase 1 / Phase 2	Completed	MorphoSys AG	96	2009-12-01	2014-10-24

Conditions studied

Arthritis, Rheumatoid (8) · COVID-19 (1) · Coronavirus Infections (1) · Multiple Sclerosis (1) · Osteoarthritis (1) · Pain (1) · Severe Acute Respiratory Syndrome (1)

Countries

Poland (10) · Germany (8) · United Kingdom (8) · Spain (6) · United States (6) · Hungary (5) · Russia (5) · Argentina (4) · Bulgaria (4) · Canada (4) · Italy (4) · Japan (4) · Mexico (4) · South Africa (4) · Belgium (3)

Top investigators

Roman P Korolkiewicz, MD, PhD (2)

Results publications

PMID 24534756, PMID 37696589, PMID 37699654, PMID 38273625, PMID 40044198

NIH funding

2015 (2), 2014 (1)